<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="P0b002ee18038ece1">
<name type="corporate">
 <namePart>United States Government Publishing Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
  <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
</role>
 <role>
  <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
  <roleTerm authority="marcrelator" type="code">dst</roleTerm>
</role>
</name>
<name type="corporate">
 <namePart>United States</namePart>
 <namePart>Government Accountability Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">author</roleTerm>
  <roleTerm authority="marcrelator" type="code">aut</roleTerm>
</role>
 <description>Government Organization</description>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">government publication</genre>
<language>
 <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<extension>
 <collectionCode>GAOREPORTS</collectionCode>
 <category>Legislative Agency Publications</category>
 <waisDatabaseName>gao</waisDatabaseName>
 <branch>legislative</branch>
 <dateIngested>2010-08-12</dateIngested>
</extension>
<originInfo>
 <publisher>U.S. Government Printing Office</publisher>
 <dateIssued encoding="w3cdtf">2001-09-07</dateIssued>
 <issuance>monographic</issuance>
</originInfo>
<physicalDescription>
 <note type="source content type">deposited</note>
 <digitalOrigin>born digital</digitalOrigin>
 <extent>50 p.</extent>
</physicalDescription>
<classification authority="sudocs">GA 1.13:GAO-01-1129</classification>
<identifier type="uri">https://www.govinfo.gov/app/details/GAOREPORTS-GAO-01-1129</identifier>
<identifier type="local">P0b002ee18038ece1</identifier>
<identifier type="former package identifier">f:d011129</identifier>
<recordInfo>
 <recordContentSource authority="marcorg">DGPO</recordContentSource>
 <recordCreationDate encoding="w3cdtf">2010-08-12</recordCreationDate>
 <recordChangeDate encoding="w3cdtf">2011-03-28</recordChangeDate>
 <recordIdentifier source="DGPO">GAOREPORTS-GAO-01-1129</recordIdentifier>
 <recordOrigin>machine generated</recordOrigin>
 <languageOfCataloging>
  <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</languageOfCataloging>
</recordInfo>
<accessCondition type="GPO scope determination">fdlp</accessCondition>
<extension>
 <docClass>REPORT</docClass>
 <accessId>GAOREPORTS-GAO-01-1129</accessId>
 <reportNumber>GAO-01-1129</reportNumber>
 <subject>Health hazards</subject>
 <subject>Consumer protection</subject>
 <subject>Product safety</subject>
 <subject>Drugs</subject>
 <subject>Economic analysis</subject>
 <subject>Elderly persons</subject>
 <subject>FDA/FTC Operation Cure.All</subject>
 <type>Other Written Product</type>
 <accountNo>A01760</accountNo>
 <USCode title="21">
                      <section number="374"></section>
                </USCode>
</extension>
<titleInfo>
 <title>Health Products for Seniors: &quot;Anti-Aging&quot; Products Pose Potential for Physical and Economic Harm</title>
</titleInfo>
<abstract>Dietary supplements marketed as anti-aging therapies may pose a
potential for physical harm to senior citizens. Evidence from the
medical literature shows that a variety of frequently used	 
dietary supplements can have serious health consequences for	 
seniors. Particularly risky are products that may be used by	 
seniors who have underlying diseases or health conditions that	 
make the use of the product medically inadvisable or supplements 
that interact with medications that are being taken concurrently.
Further, studies have found that products sometimes contain	 
harmful contaminants or much more of an active ingredient than is
indicated on the label. Unproven anti-aging and alternative	 
medicine products also pose a risk of economic harm to seniors.  
Although GAO was unable to find any recent, reliable estimates of
the overall economic harm to seniors from these products, it did 
uncover several examples that illustrate the risk of economic	 
harm. The Food and Drug Administration (FDA) and the Federal	 
Trade Commission (FTC) have identified a number of products that 
make advertising or labeling claims with insufficient		 
substantiation, some costing consumers hundreds or thousands of  
dollars apiece. The potential for harm to senior citizens from	 
health products making questionable claims has been a concern for
public health and law enforcement officials, and federal and	 
state agencies have activities under way to protect consumers of 
these products. FDA and FTC sponsor programs and provide	 
educational materials for senior citizens to help them avoid	 
health fraud. At the state level, agencies are working to protect
consumers of health products by enforcing state consumer	 
protection and public health laws, although anti-aging and	 
alternative products are receiving limited attention. GAO	 
summarized this report in testimony before Congress; see: Health 
Products for Seniors: Potential Harm From &quot;Anti-Aging&quot; Products, 
by Janet Heinrich, Director for Public Health Issues, before the 
Senate Special Committee on Aging. GAO-01-1139T, Sept. 10 (17	 
pages).</abstract>
<location>
 <url displayLabel="HTML rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-01-1129/html/GAOREPORTS-GAO-01-1129.htm</url>
 <url displayLabel="PDF rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-GAO-01-1129/pdf/GAOREPORTS-GAO-01-1129.pdf</url>
</location>
<identifier type="preferred citation">GAO-01-1129</identifier>
<location>
 <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/GAOREPORTS-GAO-01-1129</url>
</location>
<note>Other Written Product</note>
<extension>
 <searchTitle>GAO-01-1129; Health Products for Seniors: &quot;Anti-Aging&quot; Products Pose Potential for Physical and Economic Harm;
            </searchTitle>
</extension>
<subject>
 <topic>Health hazards</topic>
 <topic>Consumer protection</topic>
 <topic>Product safety</topic>
 <topic>Drugs</topic>
 <topic>Economic analysis</topic>
 <topic>Elderly persons</topic>
 <topic>FDA/FTC Operation Cure.All</topic>
</subject>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Code</title>
  <partNumber>Title 21 Section 374</partNumber>
</titleInfo>
 <identifier type="USC citation">21 U.S.C. 374</identifier>
</relatedItem>
</mods>